Research Projects & Grants

For Profit Organization

  • A randomized, double-blind, active-controlled crossover study to evaluate the efficacy and safety of fentanyl buccal tablets compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain, followed by a 12-week open-label extension to evaluate the impact of fentanyl buccal tablets on patient outcomes (Protocol #C25608/3056/BP/US), Role: Investigator, Cephalon Inc., (11/2009 - 11/2010) Status: Completed
  • A randomized, double-blind, placebo-controlled multi-center study to evaluate the safety and efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the treatment of breakthrough cancer pain (INS-05-001), Role: Investigator, InSys Therapeutics, Inc., (08/2009 - 08/2010) Status: Completed
  • A double blind, randomized, placebo controlled, parallel group dose-range exploration study of Sativex® in relieving pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy, Role: Investigator, G W Pharmaceuticals, (05/2009 - 05/2010) Status: Completed
  • A multicenter, placebo-controlled, double-blind, two-phase crossover study of Nasalfent (fentanyl citrate nasal spray) in the treatment of breakthrough cancer pain (BTCP) in subjects taking regular opioid therapy (CP043/06/FCNS), Role: Investigator, Archimedes Development Ltd., (01/2009 - 01/2010) Status: Completed
  • Reducing pain in people with chronic back pain using dry and moist heat wraps, Role: Investigator, Procter & Gamble Company, (10/2008 - 10/2009) Status: Completed
  • An open-label, two-stage, phase II study to explore the titration schedule for transitioning opioid-experienced patients with non-malignant moderate to severe chronic pain from current opioid therapy to the sufentanil transdermal therapeutic system (#EN3270-201), Role: Investigator, Endo Pharmaceuticals, (06/2008 - 06/2009) Status: Completed
  • A randomized, double-blind, placebo controlled, crossover study of RWJ-333369 for the treatment of neuropathic pain in diabetic peripheral neuropathy (333369-NPP-2002), Role: Investigator, Johnson & Johnson, (02/2008 - 02/2009) Status: Completed
  • A randomized, double-blind, placebo-controlled, parallel-group with a crossover confirmation period study of RWJ-333369 for the treatment of postherpetic neuralgia (333369-NNP-2001), Role: Investigator, Johnson & Johnson, (01/2008 - 01/2009) Status: Completed
  • Multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of lenalidomide in the treatment of complex regional pain syndrome type I, Role: Investigator, Celgene, Inc., (01/2008 - 01/2009) Status: Completed
  • A randomized double-blind, placebo-controlled, two-way cross over study of analgesic efficacy of bupivacaine transdermal therapeutic system in patients with post-herpetic neuralgia, Role: Investigator, Durect Corporation, (09/2007 - 09/2008) Status: Completed
  • An open label, long term treatment evaluation of the safety of BEMATM fentanyl use for breakthrough pain in cancer subjects on chronic opioid therapy, Role: Investigator, BioDelivery Sciences International, Inc., (09/2007 - 09/2008) Status: Completed
  • A double-blind, randomized, placebo-controlled study of modafinil and morphine or oxycodone in patients with excessive daytime sleepiness due to opioid therapy, Role: Investigator, Medgenex, Inc., (03/2007 - 03/2008) Status: Completed
  • An open-label, long-term safety study to evaluate the safety of the ZR-02-01 Matrix Transdermal Fentanyl patch for the treatment of moderate to severe non-malignant chronic pain., Role: Investigator, ZARS, Inc., (07/2006 - 07/2007) Status: Completed
  • An open-label, long -term safety study to evaluate the safety of the ZR-02-01 Matrix Transdermal Fentanyl patch for the treatment of moderate to severe cancer pain., Role: Investigator, ZARS, Inc., (07/2005 - 07/2006) Status: Completed
  • A randomized, double-blinded, placebo-controlled, multicenter phase IIb study to evaluate the efficacy and safety of Multiple Alvimopan dosage regimens for the treatment of Opioid-induced bowel dysfunction in subjects with chronic pain of non-malignant origin, Role: Investigator, GlaxoSmithKline, (08/2004 - 08/2005) Status: Completed
  • A comparison of the efficacy and safety of topomax tablets versus placebo for the prophylaxis of migraine protocol CAPSS-155 (Protocol issue date: 04 August 2000, Document No: EDMS-USRA-5530809:2.0), Role: Investigator, Ortho-McNeil Pharmaceutical, (09/2001 - 09/2002) Status: Completed
  • The safety and efficacy of electrotransport E-TRANS (fentanyl HCI) 40 mcg for the treatment of post operative pain: a double blind, multicenter, placebo-controlled trial incorporating JCAHO Pain Management Standards, edition date: June 20, 2001., Role: Investigator, ALZA Corporation, (09/2001 - 09/2002) Status: Completed
  • A randomized, double-blind, placebo-controlled comparison of the analgesic activity of valdecoxib (SC-65872) 40 mg bid as add-on therapy to opoid medication in patients with chronic cancer pain, Role: Investigator, Searle, (07/2001 - 07/2002) Status: Completed
  • Clinical protocol for a multicenter, double-blind, randomized study of the efficacy and safety of a single dose of IV parecoxib followed by up to seven days of oral valdecoxib for the pain following laparascopic cholecystectomy, parecoxib IND# 52613, valdecoxib IND #52153, Role: Investigator, Searle, (02/2001 - 02/2002) Status: Completed
  • A randomized, double-blind, parallel-design, placebo and active controlled, multicenter, ascending dose-ranging study of the safety and efficacy of single doses of Org 41793 in the treatment of post-operative pain in ASA Class I and II surgical inpatients. (Protocol No. 139-002, dated 08 August 2000), Role: Investigator, Organon USA Inc., (09/2000 - 09/2001) Status: Completed
  • Clinical Protocol for The Safety and Efficacy o f Electrotransport (E-TRANS) Fentanyl Compared to IV PCA Morphine for the Treatment of Post-Operative Pain, IND # 41,574 (Version August 2, 2000), Role: Investigator, ALZA Corporation, (08/2000 - 08/2001) Status: Completed
  • An open, randomized, 2-way crossover study comparing the treatment chronic non-malignant pain with duragesic and oxycontin, Role: Investigator, Janssen Pharmaceutical Products, L.P., (02/2000 - 02/2001) Status: Completed
  • A phase III, multi-center, double-blind, randomized, placebo-controlled study of the reversal of opioid-induced gastrointestinal dysfunction in subjects receiving chronic opioid therapy for pain or opioid addiction. [Protocol 13C304 - Version Date as of Amendment 1, April 17, 2001], Role: Investigator, Adolor Corporation, Status: Completed
  • A multicenter, randomized, double-blind, placebo-controlled,parallel group study to assess the safety and efficacy of GW406381 25 mg and 50 mg, administered once daily for 21 days to subjects with postherpetic neuralgia, Role: Investigator, GlaxoSmithKline, Status: Completed

Internal

  • A phase II, multi-center, randomized, double-blind, placebo-controlled study of CJC-1008, a long acting, parenteral, opioid analgesic, in the treatment of surgical pain following total knee arthroplasty, IND #60,935. Protocol version: 06/22/01, Role: Investigator, LLU Dept. of Anesthesiology, (01/2002 - 01/2003) Status: Completed